NYUCI-ES: Psychosocial Intervention to Improve Health Outcomes for Chinese and Korean ADRD Caregivers
Launched by NEW YORK UNIVERSITY · Jul 13, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the NYUCI-ES, is studying how a special support program can help Chinese and Korean American caregivers who are taking care of family members with dementia. The program includes online chat groups and culturally relevant materials to better support these caregivers. Researchers want to see if this program can reduce feelings of depression and stress, improve overall health, and lower risks for conditions like diabetes and heart disease over the course of a year.
To participate in this study, you need to be a primary caregiver of Chinese or Korean descent, at least 50 years old, and living in New York City or Bergen County, New Jersey. You should be comfortable using the internet and reading in English, Chinese, or Korean. The study will include 300 caregivers, and you can expect to receive support through counseling and peer discussions, as well as educational resources about caregiving. This study aims to not only help improve your health but also to influence healthcare policies that can benefit caregivers from diverse backgrounds in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A spouse or other family caregiver of Chinese or Korean ancestry living in New York City or Bergen County New Jersey, who is willing to participate in the study (additional family members can be included in family counseling sessions if the CG is assigned to the treatment group)
- • at least 50 years of age
- • self-identified as a primary caregiver
- • have access to Internet and phone with SMS and voice messaging
- • no plans to move for 12 months
- • able to read English, Chinese, or Korean
- • capable of completing informed consent
- • meet specific cardiometabolic and depressive symptom criteria: Cardiometabolic syndrome: It will not be required to submit objective measurement of cardiometabolic disorder, self-reported medical conditions will be accepted for enrollment. Diabetes: self-reported OR A1C \>= 5.7% OR High Cholesterol: self-reported OR low-density lipoprotein (LDL) \> 130 mg/dL or total cholesterol \> 200 mg/dL (American Heart Association 2018) OR Hypertension: self-reported OR systolic blood pressure (SBP) \>= 130 mmHg or diastolic blood pressure (DBP) \>= 80mmHg (2017 ACC/AHA hypertension guideline) OR Body Mass Index \> 23 kg/m2 by self-reported or measured height and weight (WHO expert consultation regarding Asian cut-off) OR other related metabolic syndrome, such as euthyroid hypothyroxinemia.
- • care recipient regularly has trouble remembering recent events, repeat the same question over and over, or lose or misplace things
- Exclusion Criteria:
- • current alcoholic or substance abuse; and history of psychiatric diagnoses requiring hospitalization during the past 5 years.
About New York University
New York University (NYU) is a prestigious research institution renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure and a diverse team of leading experts, NYU conducts cutting-edge research across various therapeutic areas, focusing on translating scientific discoveries into effective treatments. The university fosters collaboration among multidisciplinary teams and engages with a broad patient population, ensuring that its trials adhere to the highest ethical standards and regulatory requirements. NYU's dedication to excellence in research and education positions it as a key contributor to the advancement of healthcare and clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Bei Wu, PhD
Principal Investigator
New York University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials